Vanguard Personalized Indexing Management
DNA icon

Vanguard Personalized Indexing Management’s Ginkgo Bioworks DNA Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-926
Closed -$11.3K – 1788
2024
Q2 		$11.3K Buy
926
+173
+23% +$5.16K ﹤0.01% 1678
2024
Q1 		$35K Sell
753
-537
-42% -$27.8K ﹤0.01% 1587
2023
Q4 		$87.2K Sell
1,290
-731
-36% -$44.8K ﹤0.01% 1481
2023
Q3 		$146K Buy
2,021
+64
+3% +$5.12K ﹤0.01% 1341
2023
Q2 		$146K Buy
1,957
+842
+76% +$49.8K ﹤0.01% 1377
2023
Q1 		$59.3K Sell
1,115
-904
-45% -$57.3K ﹤0.01% 1420
2022
Q4 		$136K Sell
2,019
-799
-28% -$73.5K 0.01% 1200
2022
Q3 		$352K Buy
2,818
+873
+45% +$104K 0.02% 909
2022
Q2 		$185K Sell
1,945
-1,366
-41% -$167K 0.01% 1152
2022
Q1 		$534K Buy
3,311
+2,414
+269% +$470K 0.03% 808
2021
Q4 		$298K Buy
+897
New +$426K 0.02% 865

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Personalized Indexing Management's DNA Position: Q3 2024 in Review

Vanguard Personalized Indexing Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 926 shares — an estimated $11.3K sold.

Vanguard Personalized Indexing Management first reported a position in DNA in Q4 2021 and held it in 11 quarters. The position peaked at $534K in Q1 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Vanguard Personalized Indexing Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 926 Ginkgo Bioworks shares in Q3 2024, an estimated $11.3K.
  • Vanguard Personalized Indexing Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 11 quarters.
  • Vanguard Personalized Indexing Management's Ginkgo Bioworks position peaked at $534K in Q1 2022.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Vanguard Personalized Indexing Management's 13F filing for Q3 2024, filed 12 Nov 2024.